ArticleFrontiers in immunology2024
Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Immunopharmacological effects of shikonin in experimental rheumatoid arthritis: a systematic review and meta-analysis of in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews.Frontiers in medicine · 2026Pooled it
- Global burden of pain in malignant bone tumors: a meta-analysis of severity and health outcomes.Frontiers in oncology · 2026Pooled it
- Bioinspired 0D mitochondrial bioenergetic actuators rewire cartilage progenitor cell metabolism for osteoarthritis remission.Bioactive materials · 2026Article
- Glycyrrhizic Acid Relieves Fatigue Induced by Acute and Chronic Exercise in Mice via Inhibition of the NF-κB/NLRP3 Signaling Pathway.Brain and behavior · 2026Article
- Rutin as a multi-target anti-inflammatory phytochemical in arthritic disorders: pharmacological mechanisms and therapeutic potential.Inflammopharmacology · 2026Review
- FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).International journal of molecular medicine · 2026Review
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Total Flavonoids of Rhizoma Drynariae Ameliorate Tendon-Bone Healing Following Anterior Cruciate Ligament Reconstruction in Rats by Activating the FSP1/CoQApplied biochemistry and biotechnology · 2026Article
- Influence of Genetic and Epigenetic Factors on Periodontitis Susceptibility and Treatment Outcomes.Biochemical genetics · 2026Review
- Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.Clinical and experimental medicine · 2026Review
- Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.Molecular biology reports · 2026Review
- Transcriptome Analysis of Differentially Expressed Genes and Molecular Pathways Involved During Osteoclast Differentiation.Molecular biotechnology · 2026Article
- Targeting the immunological synapse in multiple myeloma.Discover oncology · 2026Review
- Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.Immunity, inflammation and disease · 2026Review
- Applications of artificial intelligence in mechanical engineering for the field of upper limb exoskeletons.Scientific reports · 2026Article
- Syndecan-2 Regulates Integrin-β1 to Influence the Abnormal Subchondral Bone in Early-stage Knee Osteoarthritis.Applied biochemistry and biotechnology · 2026Article
- Nanocomposite hydrogels: benefits and attributes for osteoarthritis therapy.Journal of translational medicine · 2026Review
- Intrinsic capacity trajectory and hip fracture risk in Chinese middle-aged and older adults: a 10-year retrospective cohort study.Scientific reports · 2026Article
- Identified BIRC5 and HDAC1 as novel diagnostic biomarkers linked to centrosome-immune crosstalk for cutaneous squamous cell carcinoma via machine learning-based multi-omics analysis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Osteosarcoma (OS) is the primary bone tumor originating from transformed mesenchymal cells. It is unclear whether associations between specific circulating immune cells and OS are causal or due to bias. To clarify whether predicted genetically altered circulating immune cells are associated with OS development, we performed a two-sample Mendelian randomization (MR) analysis. Methods: The genetic variants strongly associated with immune cell traits as instrumental variables (IVs) were used to perform MR analyses. The effect of specific immune cells on OS risk was measured using the summary statistics from the genome-wide association studies (GWAS). Results: Our findings indicate that CD80 on CD62L+ myeloid dendritic cell and CD28-CD4-CD8- T-cell absolute count are positively associated with OS (CD80 on CD62L+ myeloid dendritic cell, OR: 3.41 [95% CI: 1.40 to 8.31], Conclusions: These findings illustrate that the genetic predisposition to specific immune cells can exert a causal effect on OS risk, which confirms the crucial role played by immunity in OS development. Particularly, the causal association between immune cells and OS underscores the evidence for exploring the new treatment strategy for OS in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.